VC  JDRF T1D Fund

https://www.jdrf.org/about/t1dfund/





     Office Locations:

26 Broadway, 14th Floor
New York, NY 10004
Phone: 800-533-CURE

 

Stages:

  • Early


 

Industries:

  • Life Sciences & Healthcare
  • Medical Device

  •  

    Description:

    JDRF T1D Fund is an independently managed venture philanthropy fund that will make early-stage commercial investments to accelerate life-changing type 1 diabetes (T1D) therapies. The JDRF T1D Fund will make high-impact early-stage investments to accelerate commercial development of life-changing therapies for people living with T1D. The fund is the first vehicle devoted to early-stage commercial investing in T1D; over $65 million raised to date. Through its investments in partnership with private capital, including venture capital, corporations and foundations, the T1D Fund seeks to attract the private investment necessary to advance drugs, devices, diagnostics, and vaccines into the hands of those living with T1D. The T1D Fund invests in areas strategically aligned with JDRF, with an exclusive focus on the best commercial opportunities. The T1D Fund will reinvest any realized gains into new investments to further its mission.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Jonathan Behr Managing Director
    Katie Ellias Managing Director

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      08/08/2018


      SQZ Biotech


      MA


      $72,000,000


      Series C


      03/29/2018


      Bigfoot Biomedical


      CA


      $55,000,000


      Series B


     

    Portfolio companies include:

     

    Recent News: